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Abstract
Background: The purpose of this study was to compare the safety and clinical outcomes of transcarotid 
(TC) and transapical access (TA) transcatheter aortic valve implantation (TAVI) patients whom the 
transfemoral approach (TF) was not feasible.
Methods: The analysis included consecutive patients with severe symptomatic aortic stenosis treated 
from 2017 to 2020 with TC-TAVI or TA-TAVI in two high-volume TAVI centers. The approach was 
selected by multidisciplinary heart teams after analyzing multislice computed tomography of the heart, 
aorta and peripheral arteries, transthoracic echocardiography and coronary angiography. 
Results: One hundred and two patients were treated with alternative TAVI accesses (TC; n = 49 and 
TA; n = 53) in our centers. The groups were similar regarding age, gender, New York Heart Associa-
tion class, and echocardiography parameters. Patients treated with TC-TAVI had significantly higher 
surgical risk. The procedural success rate was similar in both groups (TC-TAVI 98%; TA-TAVI 98.1%; 
p = 0.95). The rate of Valve Academic Research Consortium-2 defined clinical events was low in both 
groups. The percentage of new-onset rhythm disturbances and permanent pacemaker implantation was 
similar in TC and TA TAVI (4.1% vs. 11.3%; p = 0.17 and 10.2% vs. 5.7%; p = 0.39, respectively). 
In the TA-TAVI group, significantly more cases of pneumonia and blood transfusions were observed 
(11% vs. 0%; p = 0.01 and 30.2% vs. 12.2%; p = 0.03). The 30-day mortality was similar in TC and 
TA groups (4.1% vs. 5.7%; p = 0.71, respectively). 
Conclusion: Both TC and TA TAVI are safe procedures in appropriately selected patients and are as-
sociated with a low risk of complications. (Cardiol J)





20XX, Vol. XX, No. X, XXX–XXX
DOI: 10.5603/CJ.a2021.0071 





The first transcatheter aortic valve implanta-
tion (TAVI) described in 2002 by Cribier et al. [1] 
opened a new era of treatment of severe, symp-
tomatic aortic stenosis in high-risk or inoperable 
patients. Transfemoral (TF) is a well-known, 
minimally invasive, and safe access route for TAVI 
procedures recommended not only for high and 
intermediate-risk patients, but also for selected 
older low-risk patients [2–4]. Due to peripheral 
arterial disease, unfavorable aortoiliac anatomy, or 
diseases of the thoracoabdominal aorta, TF access 
is unavailable for approximately 15% of all TAVI 
candidates [5, 6]. The surgical antegrade transapi-
cal (TA) access, as described in 2006 by Ye et al., 
is the first-choice alternative approach in many 
centers, in case of an inability to use the TF route 
[7–9]. In 2010, Modine et al. [10] described the first 
TAVI performed via the left common carotid artery 
(CCA). Tanscarotid (TC) TAVI seems to be a safe 
alternative for patients disqualified from TF-TAVI 
[11–13]. The present study aimed to compare the 
safety, and short-term efficacy outcome of consecu-
tive patients treated TC-TAVI and TA-TAVI in two 
high-volume TAVI centers in Poland.
Methods
This retrospective analysis included consecu-
tive patients with severe symptomatic aortic steno-
sis treated between 2017 and 2019 with TC-TAVI 
or TA-TAVI in two high-volume TAVI centers. The 
retrospective registry did not require the approval 
of an institutional review board or ethics commit-
tee. The database contained anonymized datasets. 
Written informed consent for the TAVI procedure 
according to the qualification was obtained from all 
patients. The study outcomes were defined accord-
ing to the Valve Academic Research Consortium-2 
(VARC-2) consensus [14]. The choice of access (TF 
vs. alternative) site was made by The Heart Team 
based on results from multislice computed tomo-
graphy (MSCT) of the heart, aorta, and peripheral 
arteries, transthoracic echocardiography (TTE), 
and coronary angiography. For the analysis and 
reconstruction of the MSCT images, the 3Mensio 
(Pie Medical Imaging, Bilthoven The Netherlands) 
software was used. Patients with peripheral artery 
disease, including significant stenosis, extreme 
tortuosity, heavy calcifications, and small iliofemo-
ral artery diameter (< ⁠6 mm) were considered 
to have contraindications for TF-TAVI. Also, the 
thoracoabdominal aorta significant diseases includ-
ing aneurysm, chronic dissection, large thrombus, 
extreme tortuosity, previous vascular surgery, or 
presence of an aortic stent graft was an indication 
for the use of alternative access routes (TC or TA). 
The choice depended on the operator’s experience 
and preferences. The criteria for consideration of 
TC-TAVI were as follows: diameter of the CCA 
> 5.5 mm with no significant calcifications and 
no ipsi- and contralateral CCA stenosis (> 50%). 
The exclusion criteria for TA access were frailty 
syndrome, cachexia, significant coagulopathies, 
and severe lung diseases. All procedures were 
done by an experienced Heart Team in a hybrid 
operating room under general or in some cases 
of TC-TAVI under local anesthesia. The detailed 
protocol of transcarotid access was described in 
earlier publications [11, 15]. In TA-TAVI, access 
to the pericardium was achieved through the left 
anterior mini-thoracotomy. The decision on the lo-
cation of the incision was made under angiographic 
and TTE guidance. Typically, a 4–5 cm long incision 
was made at the 7th intercostal space. Then the 
pericardium was visualized and opened. An apical 
two U pledged sutures were placed slightly lateral 
and above the true apex. The heart was punctured 
with a needle, and after the introduction of 6 F vas-
cular sheath, the J-tipped wire crossed the aortic 
valve and was positioned in the descending aorta. 
Following that, the right Judkins or pigtail catheter 
was positioned, and the soft wire was exchanged for 
a stiff wire. Over the stiff wire, the Certitude sheath 
was inserted into the left ventricle. The valve was 
placed at the target position, as confirmed by root 
contrast injection. Valves were expanded during 
the rapid pacing 160–180 bpm to achieve systolic 
blood pressure below 50 mmHg. After implantation 
position of the valve and grade of paravalvular leak 
was controlled by contrast injection. All patients 
were given antibiotics (1.5 g cephazolin) as infec-
tious endocarditis prophylaxis. The heparin (100 
U/kg, target activated clotting time > 250 s) was 
administered after placement of a vascular access 
catheter (6 F) into the carotid artery in TC-TAVI 
and before cardiac puncture in TA-TAVI. Patient 
monitoring during both types of procedure includ-
ed: continuous intraarterial blood pressure, arterial 
blood saturation, electrocardiography, and addi-
tionally cerebral oximetry (Covidien, Medtronic 
plc, Ireland) in cases of the TC-TAVI cases. TTE 
was used during TC-TAVI, and transesophageal 
echocardiography was performed in TA-TAVI. The 
electrode for rapid pacing was placed through the 
6 F sheath through an internal jugular vein or 
femoral vein. External defibrillator pads were 
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also placed. Post dilatation was performed if the 
angiographic and echocardiographic evaluation of 
paravalvular leak was moderate or larger. Prota-
mine was given after removing the instruments 
and tightening sutures. After TC-TAVI, the selec-
tive arteriography was performed for control of 
CCA patency. The eligibility criteria, methods, and 
technics of TA-TAVI and TC-TAVI procedures did 
not differ at both centers.
Statistical analysis
Categorical data were presented as numbers 
(%). The Kolmogorov-Smirnov test was used to 
assess the data distribution. Normally distributed 
values were presented as mean with standard 
deviation. Non-normally distributed values were 
presented as median with 25th and 75th percentile 
(interquartile range [IQR]). Continuous data were 
compared by the Student t-test or by the Mann-
-Whitney U test, depending on the distribution. 
Categorical data were analyzed with the c2 or 
the Fisher exact test. P values of < 0.05 were 
considered statistically significant. The statisti-




Between 2017–2020, 882 TAVI procedures 
were performed in the Upper-Silesian Medical 
Center of the Medical University of Silesia in 
Katowice and the Medical University of Gdansk. 
Most of them (88%) were TF-TAVI. This retro-
spective study enrolled 102 patients treated with 
alternative TAVI accesses (TC; n = 49 and TA; 
n = 53). The baseline characteristics of the patients 
are presented in Tables 1 and 2. The groups were 
Table 1. Baseline and demographic data.\
Variables TC-TAVI (n = 49) TA-TAVI (n = 53) P
Age [years] 78 (72–85) 78 (71–81) 0.30
Male 26 (53.1) 30 (56.6) 0.72
Body mass index [kg/m2] 28 (24.8–31.2) 27 (24.7–29.2) 0.45
NYHA class 3 (3–3) 3 (3–3) 0.12
EuroSCORE II [%] 8.0 (4.8–10.9) 5.7 (2.9–8.2) 0.009
Cardiac comorbidities
Prior myocardial infarction 17 (34.7) 20 (37.7) 0.75
Prior cardiac operation 13 (26.5) 24 (45.3) 0.05
Prior PCI 25 (51) 18 (34) 0.08
Hypertension 48 (98) 47 (88.7) 0.06
Bicuspid aortic valve 11 (22.4) 8 (15.1) 0.34
Other comorbidities
Diabetes mellitus 22 (44.9) 23 (43.4) 0.88
COPD 13 (26.5) 10 (18.9) 0.36
Peripheral arterial disease 22 (44.9) 27 (50.9) 0.54
Abdominal aortic aneurysm 8 (16.3) 2 (3.8) 0.03
Atrial fibrillation 16 (32.7) 15 (28.3) 0.63
Hypertension 48 (98) 47 (88.7) 0.06
Thrombus in aorta 18 (36.7) 10 (18.9) 0.04
Blood test results
GFR [mL/min/1.73 m2] 61.0 (48.5–70.2) 56 (43.7–66.7) 0.21
Hemoglobin level [g/L] 12.9 (11.8–14.2) 12.5 (10.9–13.4) 0.03
Hematocrit [%] 39.7 (35.5–42.1) 37.3 (32.9–39.8) 0.01
Platelet level × 103/μL 173 (153–224.5) 207 (162.2–257.7) 0.04
WBC level × 103/μL 7.1 (6.0–8.6) 7.2 (6.0–8.6) 1.00
Data are given as the median (interquartile range) or as number (%); COPD — chronic obstructive pulmonary disease; GFR — glomerular 
filtration rate; NYHA — New York Heart Association; PCI — percutaneous coronary intervention; TAVI — transcatheter aortic valve implantation; 
TA — transapical access; TC — transcarotid access; WBC — white blood cells
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similar regarding age (78 [72–85] vs. 78 [71–81]; 
p = 0.30), gender (53.1% males vs. 56.6%; 
p = 0.72), baseline New York Heart Association 
(NYHA) class and echocardiography parameters 
(left ventricular ejection fraction; aortic valve area; 
aortic valve maximal gradient [PGmax], aortic 
valve mean gradient [PGmean]; transaortic peak 
instantaneous velocity [Vmax]). Patients treated 
with TC-TAVI more often had a pathology of the 
abdominal aorta (aneurysm, extreme tortuosity, 
and thrombus) (16.3% vs. 3.8%; p = 0.03 and 36.7% 
vs. 18.9%; p = 0.03, respectively). Additionally, 
their surgical risk assessed by EuroSCORE II 
was significantly higher (8.0 [4.8–10.9] vs. 5.7 
[2.9–8.2]; p = 0.009) than the TA group. In preop-
erative blood tests there were differences between 
the TC and TA group in the level of hemoglobin 
(12.9 [11.8–14.2] vs. 12.5 [10.9–13.4]; p = 0.03), 
hematocrit (39.7 [35.5–42.1] vs. 37.3 [32.9–39.8]; 
p = 0.01) and platelets (173 [153–224.5] vs. 207 
Table 2. Perioperative and postoperative outcomes.
Variables TC-TAVI (n = 49) TA-TAVI (n = 53) P
Perioperative
Procedural success 48 (98.0) 52 (98.1) 0.95
Procedural time [min] 65 (60.0–76.2) 110 (80.0–120.0) < 0.0001
General anesthesia 47 (95.9) 53 (100) 0.39
Valve prosthesis size 29.0 (26.0–29.0) 26.0 (23.0–26.0) < 0.0001
Balloon aortic predilatation 5 (10.2) 0 (0) 0.01
Balloon aortic postdilatation 10 (20.4) 5 (9.4) 0.12
Coronary occlusion 0 (0) 1 (1.9) 0.33
Intraoperatively inotropic drugs 11 (22.4) 15 (28.3) 0.50
Temporary pacemaker > 24 hours 9 (18.4) 8 (15.1) 0.66
Postoperative
Myocardial infarction 1 (2.0) 2 (3.8) 0.60
Life-threatening bleeding 0 (0) 1 (1.9) 0.33
Blood transfusion 6 (12.2) 16 (30.2) 0.03
Transient ischemic attack 3 (6.1) 1 (1.9) 0.23
Stroke 0 (0) 1 (1.9) 0.86
Tamponade 1 (2.0) 2 (3.8) 0.60
Minor vascular complication 2 (4.1) 2 (3.8) 0.93
Mechanical ventilation time [min] 160.0 (92.5–360) 200 (160.0–315) 0.07
ICU stay [days] 2 (2–3) 3 (2–4) 0.21
Hospital stay [days] 6 (6–7) 7 (5–8) 0.03
NYHA class on discharge 1 (1–2) 2 (1–2) 0.003
Pneumonia 0 6 (11.5) 0.01
New-onset atrial fibrillation 2 (4.1) 6 (11.3) 0.17
Permanent pacemaker implantation 5 (10.2) 3 (5.7) 0.39
In-hospital mortality 1 (2.0) 2 (3.8) 0.60
Short-term follow-up mortality 2 (4.1) 3 (5.7) 0.35
Blood test results
GFR [mL/min/1.73 m2] 62.5 (48–79.5) 60 (47–72) 0.27
Hemoglobin level [g/L] 11.2 (9.9–11.9) 10.7 (9.6–11.7) 0.17
Hematocrit [%] 33.4 (30.1–35.4) 33.0 (28.8–35.1) 0.47
Platelet level × 103/μL 139 (116–162) 157 (123.5–192.7) 0.04
WBC level × 103/μL 6.8 (5–8.8) 9 (6.8–11.4) 0.0002
Data are given as the median (interquartile range) or as number (%); GFR — glomerular filtration rate; ICU — intensive care unit; TAVI — tran-
scatheter aortic valve implantation; TA — transapical access; TC — transcarotid access; WBC — white blood cells
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[162.2–257.7]; p = 0.04), respectively. However, 
the number of patients with anemia by definition 
of the World Heart Organization was similar (TC: 
15/49 [31%] vs. TA: 22/53 [41.5%]; p = 0.25). 
Both groups did not show statistically significant 
differences in terms of other blood test results and 
comorbidities. 
Perioperative outcomes
All TA-TAVI and most TC-TAVI (95.9%) were 
made under general anesthesia (p = 0.13). There 
were differences in terms of type of prosthesis 
used. Balloon-expandable (BE) Sapien 3 aortic 
valve prosthesis (Edwards Lifesciences Corp., 
Irvine, CA, USA) were implanted in all procedures 
performed via TA access. In the TC-TAVI group 
both BE valves were used (Edwards-Sapien 3 Ultra 
in 26.5% of cases), as well as self-expandable (SE) 
valves (Evolute R [Medtronic, Minneapolis, MN, 
USA] and Portico [Abbott Vascular, Santa Clara, 
CA, USA] in 71.5% and 2% of cases, respectively). 
In patients treated with TC-TAVI, significantly 
larger valve sizes were used (29 [26–29] mm vs. 
26 [23–26] mm; p < 0.0001). The median proce-
dure time was significantly shorter in TC group 
(65 [60–76.2] min vs. 110 [80–120] min; p < 0.0001). 
In this group, there was a higher percentage of 
balloon predilatation (5% vs. 0%; p = 0.01) than in 
TA. No statistically significant differences in other 
procedural parameters were noted (Table 3).
The procedural success rate was high and 
were similar in both groups: TC-TAVI 98%; TA-
-TAVI 98.1% (p = 0.95). One patient died during 
TC-TAVI, and 2 patients died during TA-TAVI 
(p = 0.60). A low rate of neurological complications 
was observed in both groups (only 1 stroke in TA 
group [1.9%] vs. none in TC group; p = 0.33 and 
1 transient ischemic attack [1.9%] vs. 3 [6.1%]; 
p  = 0.27, respectively). The rate of other events 
was assessed according to VARC-2 was low and did 
not differ between groups (coronary artery occlu-
sion [0% vs 1.9%; p = 0.33], myocardial infarction 
[2% vs. 3.8%; p = 0.6], life-threatening or disabling 
bleeding [0% vs. 1.9%; p = 0.33], major and minor 
vascular complications [4.1% vs. 3.8%; p = 0.93] 
and acute renal failure with need of dialysis [0% 
vs. 1.9%; p = 0.33]). None of the patients required 
conversion to surgical valve replacement due to 
prosthetic dislocation or dysfunction.
In-hospital outcomes
The median time patients spent in the intensive 
care unit was similar (2 [2–3] vs. 2 [2–3]; p = 0.66]) 
while the median hospitalization time was shorter 
in TC group (6 [5–7] vs. 7 [5–8]; p = 0.03). The 
percentage of new-onset atrial fibrillation and per-
manent pacemaker implantation was similar in TC 
and TA TAVI (4.1% vs. 11.3%; p = 0.17 and 10.2% 
vs. 5.7%; p = 0.39, respectively). Prolonged post-
operative temporary pacing was required in 18.4% 
of patients with the TC approach and 15.1% with 
TA (p = 0.65). In the TA-TAVI group, significantly 
more cases of pneumonia and blood transfusions 
were observed (11% vs. 0%; p  = 0.01 and 30.2% 
vs. 12.2%; p = 0.03). Total postoperative drain-
age was small 330.0 mL (220.5–482.5 mL) in TA 
patients. Local complications were rare and only 
related to wound hematoma (TC 4.1%, TA 1.9%; 
p = 0.51). There was no wound infection or pneu-
mothorax in any of the groups. In the control TTE 
similar ejection fraction was observed as well as 
a significant reduction in aortic stenosis param-
eters (PGmax, PGmean, and Vmax). The median 
NYHA functional class significantly decreased as 











LVEF [%] 50 (41–60) 50 (40–55) 0.23 55 (50–60) 50(40–55) 0.03
PGmean [mmHg] 44 (36–54) 44 (38–51) 0.83 8 (6–11)* 10 (8–12)* 0.02
PGmax [mmHg] 73 (63–86) 73 (63–85) 0.91 15 (13–20)* 18 (15–21)* 0.03
Vmax [m/s] 4.1 (3.9–4.6) 4.3 (3.8–4.6) 0.57 2 (1.8–2.3)* 2 (1.9–2.3)* 0.27
Paravalvular leak > 2 grade – – – 2 (4.2) 0 (0) 0.41
Data are presented as the median (interquartile range) or as number (%). *An asterisk indicated values statistically different from the preopera-
tive values (p < 0.001); LVEF — left ventricular ejection fraction; PGmax — aortic valve maximal gradient; PGmean — aortic valve mean gradi-
ent; TAVI — transcatheter aortic valve implantation; TA — transapical access; TC — transcarotid access; Vmax — transaortic peak instantane-
ous velocity
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compared to the initial values (Table 2, Fig. 1). 
Postprocedural echocardiography results were 
showed slightly lower transvalvular gradients 
in the TC group (PGmax 15.5 [13–20.5] vs. 18.5 
[15.5–21]; p = 0.03), PGmean 8.5 [6–11] vs. 10 
[8–12]; p = 0.02), ejection fraction 55 [50–60] vs. 
50 [40–57.5]; p = 0.03). In the control laboratory 
test results had differences between the TC and 
TA group in the white blood cells level (6.8 [5–8.8] 
vs. 9 [6.8–11.4]; p = 0.0002) and platelets (139 
[116–162] vs. 157 [123.5–192.70]; p = 0.04). 
Short-term outcomes
The final NYHA class was lower in TC group 
(1 [1–2] vs. 2 [1–2]; p = 0.003). The 30-day mor-
tality was similar in TC and TA groups (4.1% vs. 
5.7%; p = 0.71, respectively). 
Discussion
Selection of the alternative access
Data herein, shows that the use of an alterna-
tive to TF access routes pertains to a relatively 
small population of approximately 12% of TAVI-
-eligible patients. The registry evaluated the data 
of 102 consecutive patients treated with non-TF 
TAVI accesses. Both groups were comparable in 
sample size, age, gender, heart failure class, and 
baseline echocardiographic parameters. The dif-
ferences between groups are mainly related to the 
operative EuroSCORE II risk and the frequency of 
aortic pathology (aneurysm, thrombus) which were 
significantly higher in the TC group. On the other 
hand, the patients treated with the TA approach 
more often had a history of cardiac surgery. There 
were some differences in the baseline hemoglobin 
levels; however, they were not marked, and the 
frequency of anemia was similar. Patient selection 
is crucial because TF access provides the lowest 
risk of complications, and the decision to switch 
to an alternative access should be based on thor-
ough Heart Team discussion [16, 17]. TA access, 
as the more invasive, is currently used less across 
Europe and the United States of America than in 
the early era of TAVI (a decline from 17% to 4% 
in French registries) as seen in the Society of 
Thoracic Surgeons/American College of Cardiol-
ogy Transcatheter Valve Therapy Registry [5, 18].
Procedural data
There are obvious differences in procedural 
setup for both procedures because all patients 
treated with TF were under general anesthesia 
while some of the TC were operated under deep 
conscious sedation. Also, the TC patients were 
monitored uniformly by cerebral oximetry. It was 
shown that this approach leads to a low risk of 
cerebrovascular complications and has favorable 
outcomes [11].
Because of the prosthetic valve design, only BE 
Sapien 3 valves were implanted in patients with TA 
access. For TC access, the choice of the valves was 
broader and included both BE and SE (Evolute R 
and Portico). Interestingly, in patients treated with 
TC-TAVI, significantly larger valve sizes were used 
(29 vs. 26 mm), which might have influenced the 
residual gradients in favor of SE valves. However, 
for both types of valves, the final gradients were 
acceptable. Use of SE valves is required more often 
than in TA group balloon predilatation. The median 
procedure time was significantly shorter in the TC 
group. In our opinion, the choice of valve for TC 
TAVI should be based on the same criteria as in 
the planning of TF procedures. Both BE, and two 
types of SE valves (Evolut or Portico) can be used 
through TC access. In the case of BE valve, we 
use a standard delivery sheath, and for SE valves, 
we prefer to deliver them sheathless. For patients 
with a smaller body size and narrower CCA, the 
sheathless SE valves may be preferable. 
Procedural outcomes
The procedural success rate was high and 
comparable in both groups. There were 3 peripro-
cedural deaths (1 in TC and 2 in TA group) which 
corresponds to the high procedural risk, more dif-
fuse atherosclerosis in this group. Reassuringly, 
there was a low rate of neurological complications 
Figure 1. Changes in the New York Heart Association 
(NYHA) class before and after transcatheter aortic valve 
implantation (TAVI) — a comparison of transcarotid and 
transapical TAVI.
Before TAVI
Transcarotid TAVI Transapical TAVI
Before TAVIPost TAVI Post TAVI
NYHA I
p = 0.001 p = 0.007













in both groups (only 1 stroke). The rate of other 
events assessed according to VARC-2 was low 
and did not differ between groups, and no patients 
required conversion to surgical valve replacement 
due to prosthetic dislocation or dysfunction.
Despite the fact that in experienced hands, TA 
access is a safe treatment option, periprocedural 
mortality is higher than for patients treated through 
the TF approach. Registries show a difference in 
30-day mortality of 5% vs. 1.6% in favor of TF [19]. 
Most likely, a patient’s anatomy and comorbidities 
are key factors in this difference. Also, in some 
patients with frailty syndrome and left ventricle 
scar related to a history of myocardial infarction, 
a surgical procedure using the 24 F delivery sys-
tem has inherent limitations, and rehabilitation is 
prolonged [20]. 
In-hospital outcomes
The median time patients spent in the in-
tensive care unit was similar, while the median 
hospitalization time was shorter in the TC group. 
No differences were noted with regard to new-
onset rhythm and conduction disturbances. The 
need for permanent pacemaker implantation was 
10.2% vs. 5.7% in TC vs. TA and is consistent with 
higher use of SE valves in the TC group. TA-TAVI 
was associated with more cases of pneumonia and 
blood transfusions. Local complications were rare 
and were only related to a wound hematoma but 
without infections. In the control TTE, similar 
ejection fraction was observed and a significant 
reduction in aortic stenosis parameters. There 
were slightly lower transvalvular gradients in 
the TC group which is consistent with the use of 
larger devices.
Short-term outcomes
The median NYHA functional class signifi-
cantly decreased as compared to initial values, and 
the NYHA class 1 was more frequent in TC group, 
which can be related to more rapid ambulation and 
rehabilitation after this artery-based approach. The 
30-day mortality was similar in TC and TA groups 
despite the fact that surgical risk was significantly 
higher in the TC group. In comparison to the re-
cent metanalysis of Wee et al. [21], which reported 
6.5% 30-day mortality and 3.8% of cerebrovascular 
complications, the present study outcomes tend to 
be more favorable. In particular, the rate of vascular 
complications and bleeding reported by Wee et al. 
[21] was as high as 7.7% and 14.3%, which are 
much higher than the current experience.
Limitations of the study
This is a retrospective registry, and the num-
ber of cases in both groups is limited; it does 
however, reflect current practice with a very high 
use of TF access. The selection of patients was for 
a particular type of alternative access was based 
on the local experience and protocols in both cent-
ers. In addition, the results may be slightly biased 
because, compared to the TC-TAVI group, only BE 
aortic valve prosthesis were used in the TA-TAVI 
group. On the other hand, such an approach allows 
the operators to master the operational technique 
of alternative access and provides consistent re-
sults. Also, it is highly unlikely that the randomized 
trial would be feasible in these patient populations. 
The strength of this registry is a complete follow-
up and adheres to consistent institutional protocols. 
Conclusions
In conclusion, alternative access for TAVI is 
required in approximately 10% of patients. The 
choice of access should be based on the anatomy 
and an operator’s experience. Both TC and TA are 
safe procedures in appropriately selected patients, 
and procedures are associated with a low risk of 
complications. 
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